Disclosure of notification received from FMR LLC Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received a notification from FMR LLC. Notification by FMR LLC On 21 November 2024, Fagron received a notification that the shareholding of Fidelity Management & Research Company LLC, a controlled undertaking of FMR LLC, crossed the disclosure threshold of 3% upwards on 18 Nov...
Openbaarmaking van kennisgeving ontvangen van FMR LLC Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 26 november 2024 – 18u45 CET Openbaarmaking van kennisgeving ontvangen van FMR LLC Fagron heeft een kennisgeving ontvangen op grond van de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen van FMR LLC. Kennisgeving van FMR LLC Op 21 november 2024 heeft Fagron een kennisgeving ontvangen dat het aandeelhouderschap van Fidelity Management & Research Company LLC, een onderneming onder controle van FMR LLC,...
With 2 changes in our Dynamic Top Pick list (we add Azelis and we remove Solvay) we maintain a defensive stance on the market for 2H24. The long anticipated interest rate cuts by central banks have finally started. The Trump election victory in the US does not bode well for European stocks as he favours a protectionist course. Although industrial companies with a US base could actually benefit. Cleantech names with exposure to the US could also suffer (unless owned by E.Musk). We expect the US ...
EQS-News: ABOUT YOU Holding SE / Key word(s): Capital Markets Day ABOUT YOU Holding SE: ABOUT YOU Announces Strategic Vision and Financial Outlook for SCAYLE - Double-Digit Top- and Bottom-Line Growth in B2B Enterprise Commerce 07.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE ABOUT YOU ANNOUNCES STRATEGIC VISION AND FINANCIAL OUTLOOK FOR SCAYLE DOUBLE-DIGIT TOP- AND BOTTOM-LINE GROWTH IN B2B ENTERPRISE COMMERCE Hamburg | November 7, 2024 – ABOUT YOU Holding SE is set to host a virtual Capital Markets Event...
EQS-News: ABOUT YOU Holding SE / Schlagwort(e): Kapitalmarkttag ABOUT YOU Holding SE: ABOUT YOU stellt strategische Vision und finanziellen Ausblick für SCAYLE vor - Zweistelliges Wachstum beim Umsatz und bereinigten EBITDA im B2B Enterprise Commerce 07.11.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG ABOUT YOU STELLT STRATEGISCHE VISION UND FINANZIELLEN AUSBLICK FÜR SCAYLE VOR ZWEISTELLIGES WACHSTUM BEIM UMSATZ UND BEREINIGTEN EBITDA IM B2B ENTERPRISE COMMERCE Hamburg | 7. November 2024 – Die ABOUT ...
>Q3 EBITDA 6% higher than we expected - Imerys reported Q3 2024 EBITDA of € 148m (-13.9%) vs ODDO BHF estimate: € 140m (a 6% beat). TQC’s contribution came to € 5m in Q3, whereas we had expected zero. Q3 EBITDA was affected by the deconsolidation of paper (-€ 17m), a lower contribution from quartz (-€ 17m), and an increase in fixed costs (€ 21m) which were not offset by price effects (€ 4m), volumes (€ 15m) or the decrease in variable costs (€ 20m). The Q3 EBITDA marg...
>EBITDA 6% supérieur à nos attentes au T3 - Imerys a publié un EBITDA T3 2024 à 148 M€ (-13.9%) vs ODDO BHF à 140 M€ (6% au-dessus). La contribution de TQC ressort à 5 M€ au T3, nous attendions zéro. Au T3, l’EBITDA a été impacté par la déconsolidation du papier (-17 M€), la moindre contribution du quartz (-17 M€), la hausse des coûts fixes (-21 M€), non compensé par les effets prix (4 M€), les effets volumes (15 M€) et la baisse des coûts variables (20 M€). La marge...
>Results in line with estimates, organic growth at 0.9% - Vidrala results came in line with estimates with 9M 2024 organic growth in sales of +0.9% (excluding FX and consolidation effects from the recent perimeter changes in Brazil and Italy) and EBITDA at € 338m (+3% vs ODDOe, +7% y-o-y) with EBITDA margin slightly above our estimates (27.8%, +90bp). At the organic level, EBITDA recorded a +4.3% y-o-y growth. EBITDA margin reflects the positive consolidation effects ...
Following Fagron's 3Q24 update, we update our FY24 outlook to reach the upper end of the revenue guidance of € 850-870m. In the coming quarters and years, we expect sustained solid performance across business units, as the company continues to benefit from increased outsourcing of pharmaceutical compounding and its operational excellence initiatives. We reiterate our € 24 TP, reflecting 27% upside vs the current share price, hence reiterate our Buy rating.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.